Autosomal Recessive Spastic Paraplegia Type 67 (SPG67)

Autosomal Recessive Spastic Paraplegia type 67 (SPG67) is a very rare, inherited nerve disease. It mainly makes the legs stiff and weak over time. Doctors call this “spastic paraplegia.” Children often start with slow development, balance problems, and tight leg muscles. Many also have learning problems. Some have tremor in hands or feet, muscle thinning, and signs from the cerebellum (the balance part of the brain), such as shaky walking or poor coordination. The condition is autosomal recessive. That means a child gets one non-working copy of the same gene from each parent. The gene involved is PGAP1, which helps build a special “anchor” (called a GPI anchor) that holds some proteins on the cell surface. When PGAP1 does not work, many anchored proteins do not process correctly. This disrupts brain and spinal cord pathways that control movement, leading to stiff, weak legs, and other problems. NCBI+3orpha.net+3search.thegencc.org+3

SPG67 is a rare, inherited disorder in which stiffness and weakness slowly increase in both legs. It is caused by mutations in PGAP1, a gene required for healthy cell membranes. The condition primarily affects the long nerve tracts that run from the brain down the spinal cord (the “pyramidal tracts”). There is no proven cure yet, so treatment focuses on stretching tight muscles, improving walking, controlling bladder symptoms, preventing falls, and supporting daily activities. Clinical guidelines for HSP emphasize that therapy is symptomatic and multidisciplinary. NCBI+1

Other names

• SPG67 (short name used by doctors). malacards.org

• Autosomal recessive spastic paraplegia type 67 (full disease name). orpha.net

• You may also see PGAP1-related spastic paraplegia or PGAP1-related neurodevelopmental disorder in research papers. genecards.org

Types

Doctors often sort hereditary spastic paraplegias into “pure” and “complex.” SPG67 is a complex HSP. That means leg stiffness and weakness occur plus other features, such as developmental delay, tremor, and cerebellar signs. Onset is most often in infancy or childhood. Prevalence is well below 1 in a million worldwide. malacards.org

Causes

SPG67 has one core cause—pathogenic variants in the PGAP1 gene—but there are many ways this appears. Below are “causes” understood as genetic/mechanistic drivers and risk settings that lead to the same final problem (impaired GPI-anchor processing and corticospinal tract dysfunction):

1. Biallelic PGAP1 variants. A child inherits two non-working copies (one from each parent). This is required for disease. search.thegencc.org

2. Loss-of-function mutations. Frameshift, nonsense, or splice-site changes can stop the protein from being made correctly. genecards.org

3. Damaging missense mutations. A single amino acid change can prevent normal enzyme activity. genecards.org

4. Defective GPI-anchor inositol deacylation. PGAP1’s job is to remove a fatty chain on the inositol ring; if this fails, anchors do not mature. maayanlab.cloud

5. Mis-trafficking of GPI-anchored proteins. Faulty processing can block normal movement of these proteins from ER to Golgi to cell surface. NCBI

6. Reduced surface expression of key neural proteins. Neurons rely on many GPI-anchored proteins; lower levels impair synapses and pathways. maayanlab.cloud

7. Corticospinal tract dysfunction. Long motor pathways degenerate or under-function, causing spasticity and weakness in legs first. (HSP hallmark.) PMC

8. Cerebellar involvement. Some patients show cerebellar signs due to secondary effects on balance circuits. malacards.org

9. White-matter connectivity changes. Complex HSPs often show tract changes on MRI that correlate with spasticity and ataxia. PMC

10. Founder variants in some populations. In families with related parents, the same harmful variant can appear in many children. PMC

11. Compound heterozygosity. Two different harmful PGAP1 variants—one on each allele—can cause disease. search.thegencc.org

12. ER quality-control stress. Faulty anchor processing can stress the endoplasmic reticulum and affect neuron health. maayanlab.cloud

13. Neuronal membrane microdomain disruption. GPI-anchored proteins help organize cell-surface microdomains important for signaling. maayanlab.cloud

14. Developmental brain effects. Because GPI anchors affect many proteins, early brain development and myelination may be altered. PMC

15. Axonal transport strain in long pathways. Long corticospinal axons are sensitive to membrane and trafficking defects. PMC

16. Secondary motor-neuron stress. Poor synaptic signaling can increase motor-neuron workload and vulnerability. PMC

17. Aberrant synapse pruning/signaling. Disrupted surface proteins can change synapse tuning in childhood, echoing in later motor control. PMC

18. Genetic background modifiers. Other small genetic differences can shape how severe symptoms become. (Common across HSPs.) PMC

19. Environmental stressors (nonspecific). Illness, malnutrition, or injuries do not cause SPG67 but may unmask or worsen function. (General HSP principle.) Frontiers

20. Delayed recognition in low-resource settings. Not a biological cause, but late diagnosis can allow preventable complications (contractures, falls). (HSP care literature.) Frontiers

Symptoms

1. Leg stiffness (spasticity). Muscles feel tight; legs resist movement; walking becomes stiff or scissoring. malacards.org

2. Leg weakness. Climbing stairs and rising from a chair are hard; fatigue comes quickly. PMC

3. Tremor in hands or feet. A fine shaking may appear, especially during movement. malacards.org

4. Increased reflexes. Knee jerks are brisk; tapping produces big kicks; toes go up (Babinski). malacards.org

5. Developmental delay. Sitting, standing, walking, and speech may be later than typical. malacards.org

6. Learning difficulties. Many have mild intellectual disability; school tasks may be harder. malacards.org

7. Balance problems (ataxia). Unsteady steps and frequent falls occur, especially on uneven ground. malacards.org

8. Poor coordination. Fine tasks (buttoning, drawing) can be clumsy. malacards.org

9. Muscle thinning (atrophy). Some muscles look smaller over time, often in the legs. malacards.org

10. Toe-walking or scissoring gait. Tight calf and thigh muscles change the walking pattern. PMC

11. Spasms or cramps. Painful tightening can occur, especially at night or with sudden moves. Frontiers

12. Fatigue and low endurance. Walking long distances is hard; rest periods increase. Frontiers

13. Speech issues. Some children speak late or have articulation problems. PubMed

14. Behavioral or attention problems (in some). These may be mild and vary. PMC

15. Cerebellar signs on exam. Finger-nose testing may be shaky; rapid alternating movements are slow. malacards.org

Diagnostic tests

A) Physical Exam

1. General neurologic exam. The doctor checks muscle tone, strength, reflexes, sensation, and coordination. In SPG67, tone is high in legs, reflexes are brisk, and strength is variably reduced. Sensation is usually normal or mildly affected. PMC

2. Gait observation. The clinician watches how the person walks: narrow-base, scissoring, toe-walking, or stiff-knee patterns suggest corticospinal involvement. PMC

3. Muscle bulk and contracture check. Calf and thigh atrophy and ankle/hamstring tightening are common over time; early detection helps therapy planning. Frontiers

4. Developmental assessment (children). Gross and fine motor milestones, speech, and social skills are measured to define delay patterns typical of complex HSP. malacards.org

5. Cerebellar bedside tests. Finger-to-nose, heel-to-shin, and tandem gait show tremor or ataxia in some patients. malacards.org

B) Manual (bedside) neurologic maneuvers

6. Passive range-of-motion with spasticity scales. Using the Modified Ashworth Scale helps grade stiffness and monitor response to therapy. Frontiers

7. Babinski and other pyramidal signs. Stroking the sole may lift the big toe upward (extensor plantar response), a classic upper-motor-neuron sign seen in SPG67. malacards.org

8. Timed walk tests (e.g., 10-meter walk). Simple timing tracks speed and endurance changes over months. Frontiers

9. Functional mobility tests (e.g., TUG). The Timed Up and Go test measures standing, walking three meters, turning, and sitting—useful for fall risk. Frontiers

10. Coordination drills. Rapid alternating movements and heel-to-shin can reveal subtle cerebellar dysfunctions found in complex HSP. PMC

C) Laboratory & Pathological tests

11. Targeted or panel-based genetic testing. The key confirmatory test is DNA sequencing showing biallelic pathogenic variants in PGAP1. Many labs use HSP gene panels or exome/genome sequencing to catch rare genes like PGAP1. search.thegencc.org

12. Copy-number analysis (exon-level CNV). Detects small deletions/duplications in PGAP1 that standard sequencing might miss. (General HSP genetics practice.) PMC

13. Variant classification (ClinVar/ACMG). Bioinformatic and laboratory evidence classify variants as pathogenic/likely pathogenic, supporting diagnosis. genecards.org

14. Metabolic screening (to exclude mimics). Basic labs (B12, copper, thyroid, very-long-chain fatty acids if peroxisomal disease suspected) rule out other treatable causes of spasticity. (General HSP work-up guidance.) ScienceDirect

15. Research-level functional studies (select centers). Some centers study GPI-anchored protein patterns in cells to support PGAP1 effects; this is not routine but can help in uncertain cases. maayanlab.cloud

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS). Often normal in HSP because the main problem is in central motor pathways, but testing helps exclude peripheral neuropathies. PMC

17. Electromyography (EMG). May show signs of upper-motor-neuron-related changes or be normal; mainly used to rule out other neuromuscular diseases. PMC

E) Imaging tests

18. Brain MRI. Some patients with SPG67 show cerebellar abnormalities; MRI also excludes other causes and documents patterns seen in complex HSPs. malacards.org

19. Spinal cord MRI. Usually normal structurally, but it helps rule out compressive or inflammatory causes of spastic paraparesis. (General HSP practice.) PMC

20. Advanced MRI (research/tertiary centers). Tractography or volumetrics can show subtle pathway changes that match symptoms; this is supportive, not required. PMC

Non-pharmacological treatments (therapies & others)

Note: Evidence in HSP specifically is limited; most recommendations draw from HSP reviews and broader spasticity/rehab science. Frontiers

1. Individualized physiotherapy (core program)
   Regular, progressive physio (stretching, strengthening, balance, and task-specific gait work) helps maintain range, slow contracture, and improve safe walking. Randomized and protocolled HSP studies show gait-adaptability and treadmill-based programs can improve stepping and obstacle negotiation; expert reviews recommend strengthening and aerobic work as pillars of care. Medscape+3Frontiers+3PubMed+3

2. Gait-adaptability treadmill training (e.g., C-Mill/AR cues)
   Ten hours over five weeks improved obstacle avoidance and adaptability in people with pure HSP, complementing usual care. Visual cues and variable stepping challenges can translate to fewer trips at home. PubMed+1

3. Stretching & spasticity self-management
   Daily hamstring, adductor, calf, and hip-flexor stretches reduce tone spikes and delay fixed contracture. Stretching is routinely recommended in HSP guidelines to keep joints moving and support comfortable sitting, standing, and transfers. Frontiers

4. Progressive resistance training
   Targeted strengthening (glutes, quads, anterior tibialis, trunk) counters disuse weakness and improves stability. HSP reviews endorse strengthening alongside flexibility work to support gait quality. Frontiers

5. Aerobic conditioning
   Stationary cycling, over-ground walking, or aquatic cardio improves endurance and reduces energy cost of walking; aerobic training is a core component of HSP rehab programs. Frontiers

6. Ankle-foot orthoses (AFOs)
   Well-fitted AFOs can improve foot clearance, step length, and ankle control. Meta-analyses and gait studies (mostly CP/stroke) show consistent improvements in kinematics and efficiency; these principles generalize to HSP gait mechanics. PMC+2PMC+2

7. Assistive devices & mobility planning
   Selecting canes, walkers, or wheeled mobility early can prevent falls, conserve energy, and maintain independence. HSP overviews emphasize mobility aids as disease progresses. Frontiers

8. Occupational therapy (home & task adaptation)
   OT optimizes bathroom safety, transfers, seating, and workspace layout; it reduces caregiver strain and fall risk while sustaining self-care and work roles. HSP management frameworks include OT as a key discipline. Frontiers

9. Bladder training & pelvic-floor therapy
   Urgency and frequency are common in HSP; behavioral strategies and pelvic-floor work can reduce accidents and complement medication if later needed. Frontiers

10. Serial casting & splinting (short-term)
    For focal tightness (e.g., ankle equinus), short casting blocks with botulinum toxin can lengthen muscle-tendon units and delay orthopedic surgery. PMC

11. Aquatic therapy
    Water buoyancy reduces spastic co-contraction, enabling longer training bouts, gait practice, and cardiovascular work with less pain. It is commonly used in spasticity rehab frameworks. Frontiers

12. Energy-conservation & fatigue pacing
    Scheduling high-effort tasks earlier in the day, planned rests, and optimizing seating and transfers can reduce falls and sustain participation. HSP guidance encourages fatigue planning. Frontiers

13. Falls-prevention program
    Home hazard review, footwear, night lighting, and hip-strengthening routines reduce injury risk as spasticity and scissoring gait progress. HSP care plans prioritize fall prevention. Frontiers

14. Speech/swallow screening when needed
    Some complex HSP forms develop dysarthria or dysphagia; SLP input prevents aspiration and supports communication if these features appear. Frontiers

15. Pain management (non-drug)
    Heat, gentle manual therapy, positioning, and graded activity help nociceptive pain from overuse or contracture; neuromodulating strategies are often paired with physio. Frontiers

16. Community exercise & FRAME-style programs
    Emerging HSP-specific feasibility work is building structured multi-domain programs blending flexibility, resistance, aerobic, and movement execution. Frontiers

17. Urinary/bowel routines
    Timed voiding, fiber/fluid plans, and constipation prevention reduce secondary spasticity triggers and improve comfort and sleep. HSP management includes bladder/bowel strategies. Frontiers

18. Psychological support & peer groups
    Coping with a progressive rare disease is hard. Counseling and HSP organizations provide education, equipment grants, and community. sp-foundation.org

19. Genetic counseling (family planning)
    Explains autosomal-recessive inheritance, carrier testing, and prenatal/PGT options for families considering pregnancy. NINDS

20. Regular multidisciplinary review
    Neurology, PM&R, PT/OT, urology, orthopedics, and social work should revisit goals, equipment, tone control, and home safety every 6–12 months. HSP reviews recommend coordinated care. Frontiers

---

Drug treatments

Important: No medication is FDA-approved specifically for SPG67/HSP. The drugs below are commonly used off-label to treat spasticity, spasms, pain, bladder symptoms, or walking impairment. Doses are typical starting ranges from FDA labels/monographs for their approved uses; clinicians must individualize and monitor. Frontiers

1. Baclofen (oral) – GABA-B agonist for spasticity
   Dose/Time: Start 5 mg three times daily; titrate every 3 days up to effect (often 20 mg TID; max per label 80 mg/day). Purpose: Reduce muscle tone/spasms. Mechanism: Decreases excitatory neurotransmission in spinal cord. Side-effects: Drowsiness, dizziness, weakness; taper slowly to avoid withdrawal. PMC

2. Tizanidine – α2-adrenergic agonist
   Dose: Start 2 mg up to TID; titrate (commonly 2–4 mg q6–8h; max 36 mg/day). Purpose: Spasticity relief with shorter action useful for evening spasms. Mechanism: Presynaptic inhibition of motor neurons. Side-effects: Sedation, hypotension, dry mouth; taper to avoid rebound hypertension.

3. Dantrolene – direct muscle relaxant
   Dose: Typical 25 mg daily → 25 mg TID → 50 mg TID as tolerated. Purpose: Lowers severe tone by acting on skeletal muscle. Mechanism: Blocks ryanodine receptor Ca²⁺ release in sarcoplasmic reticulum. Side-effects: Hepatotoxicity risk (monitor LFTs), weakness, fatigue. PMC

4. Diazepam – benzodiazepine
   Dose: 2–10 mg up to QID (lowest effective). Purpose: Night spasms/anxiety. Mechanism: GABA-A enhancement. Side-effects: Sedation, dependence, falls—use cautiously. FDA Access Data

5. Clonazepam – benzodiazepine for nocturnal spasms/myoclonus
   Dose: 0.5–1 mg HS (titrate carefully). Mechanism/Purpose: Enhances GABA-A to calm hyperexcitability. Side-effects: Sedation, dizziness; boxed warnings for sedation with opioids. (Note: past recalls affected some ODT lots; always verify supply.) FDA Access Data+1

6. OnabotulinumtoxinA (Botox) – focal spasticity
   Dose: Limb spasticity dosing is individualized by pattern; total dose and intervals follow label, often every ~12 weeks. Purpose: Target specific overactive muscles (adductors, calves). Mechanism: Blocks acetylcholine release at neuromuscular junction. Side-effects: Local weakness, flu-like symptoms; rare distant spread. NCBI

7. Intrathecal Baclofen (ITB) – implanted pump
   Use: For severe, generalized spasticity not controlled orally. Dosing: Screening bolus followed by implanted programmable pump with gradual titration. Purpose/Mechanism: Delivers baclofen into CSF for strong spinal antispasmodic effect with fewer systemic effects. Risks: Withdrawal/overdose if pump/catheter issues, infection. FDA Access Data+1

8. Gabapentin – neuropathic pain/paresthesia
   Dose: Often 300 mg HS → 300 mg TID; titrate. Purpose: Reduce burning/tingling leg pain that can accompany gait changes. Mechanism: α2δ-subunit modulation reduces excitatory neurotransmitter release. Side-effects: Dizziness, somnolence, edema. monarchinitiative.org

9. Oxybutynin – overactive bladder/urgency
   Dose: 5 mg 2–3×/day (or ER forms per label). Purpose: Cut urgency/frequency from detrusor overactivity. Mechanism: Antimuscarinic bladder relaxation. Side-effects: Dry mouth, constipation, cognitive effects in older adults. FDA Access Data

10. Dalfampridine (4-aminopyridine ER) – walking speed (MS-approved)
    Dose: 10 mg twice daily, ~12 h apart (contraindicated in seizures/renal impairment). Purpose in HSP (off-label): May improve walking endurance in some; small pilot suggests PT+fampridine could enhance muscle properties. Mechanism: Potassium-channel blocker that improves conduction in demyelinated axons. Risks: Seizures if overdosed or in CKD. FDA Access Data+1

11. Tolterodine/other antimuscarinics – bladder control
    Alternatives if oxybutynin not tolerated; similar benefits and anticholinergic cautions. (Use per labeling.) FDA Access Data

12. Mirabegron – β3-agonist for overactive bladder
    Option when antimuscarinic side-effects are limiting; monitor BP and interactions per label. (General OAB evidence; used symptomatically in neurogenic urgency.) Frontiers

13. Analgesics (acetaminophen/NSAIDs, prudent use)
    For nociceptive pain from overuse or orthopedic strain; use lowest effective dose and GI/renal precautions. Frontiers

14. Magnesium (as adjunct, if deficient)
    Sometimes used anecdotally for cramps; evidence for general cramp reduction is mixed—check levels before supplementing and avoid excess. Cochrane Library

15. Topical botulinum or phenol neurolysis (specialist use)
    Focal chemodenervation to problem muscles or nerves when injections must be very targeted or longer-lasting; performed by experienced clinicians with clear goals. PM

---

Dietary molecular supplements

Supplements are not cures for SPG67. Use to address deficiencies, support muscle, and reduce secondary inflammation. Evidence often comes from general muscle/nerve research, not HSP-specific trials.

1. Vitamin D3 – supports muscle and balance; deficiency is common. Trials and reviews link sufficiency with better lower-limb function; consider checking 25-OH-D and supplementing to reach sufficiency. PMC+1

2. Omega-3 (EPA/DHA) – anti-inflammatory fatty acids that can lower IL-6 and improve inflammatory profiles; may help joint soreness and post-exercise recovery. Typical trial doses 1–3 g/day of combined EPA+DHA. PMC

3. Coenzyme Q10 (CoQ10) – mitochondrial antioxidant involved in energy production; reviews suggest neuroprotective potential in several neurological conditions. Common doses 100–300 mg/day with fat. PMC+1

4. Alpha-lipoic acid (ALA) – antioxidant studied in neuropathic symptoms; mixed long-term results but short-course IV/oral trials show symptomatic benefit in diabetic neuropathy; typical oral 600 mg/day. PubMed+1

5. Magnesium (if low) – essential for muscle relaxation; evidence for cramp prevention is mixed, but maintaining normal magnesium aids muscle function. 200–400 mg/day citrate or glycinate (adjust to GI tolerance). Cochrane Library+1

6. Creatine monohydrate – supports short-burst strength when combined with resistance training (typical 3–5 g/day). Can help preserve muscle in aging. The Washington Post

7. B-complex (esp. B12 if low) – correcting deficiencies supports nerve health; check levels before supplementing. NINDS

8. Protein optimization – not a capsule, but crucial: aim ~1.0–1.3 g/kg/day (higher if training/illness) spread across meals to support muscle maintenance. PMC+1

9. Mediterranean/MIND dietary pattern – emphasizes olive oil, fish, legumes, vegetables, and whole grains; linked with better brain aging and lower neuroinflammation. PubMed+1

10. Hydration & fiber – support bowel regularity and reduce tone-triggering discomfort; pair fluids with soluble fiber sources. Alberta Health Services

Drugs, immunity boosters / regenerative / stem-cell

Critical safety note: There are no FDA-approved stem-cell or regenerative drugs for HSP/SPG67. The FDA warns that most stem-cell/exosome products sold for neurologic diseases are unapproved and risky (infections, blindness, tumors). If you see clinics offering them, be cautious and ask for FDA approval numbers or IND/IRB-approved trials. U.S. Food and Drug Administration+1

• What is reasonable today: participate in regulated clinical trials (e.g., genetic studies to stratify HSP), optimize general health (vaccines, sleep, exercise, nutrition), and avoid pay-to-participate stem-cell interventions outside trials. ClinicalTrials.gov

• Why this matters: Reports document harms from unapproved stem-cell clinics; regulators continue enforcement. Until robust, peer-reviewed HSP data exist, these offerings shouldn’t be considered standard care. AP News+1

---

Surgeries (what they do & why)

1. Intrathecal baclofen pump implantation
   Procedure: Trial bolus → surgical implantation of a programmable pump in the abdomen with a catheter into the CSF. Why: For severe, generalized spasticity when pills/injections fail; allows strong tone reduction at lower systemic doses. Key risks: Infection, catheter problems, overdose/withdrawal if pump fails—managed with experienced teams. healthonline.washington.edu+1

2. Selective dorsal rhizotomy (SDR)
   Procedure: Neurosurgeon selectively cuts overactive sensory rootlets to reduce reflex overactivity. Why: In carefully selected HSP patients with disabling spasticity, SDR has reduced tone and improved standing/walking in series data; evidence is growing but not as strong as in CP. Cureus+1

3. Orthopedic tendon lengthening/osteotomy
   Procedure: Lengthening tight hamstrings/adductors/Achilles or realigning bones to correct deformity. Why: When fixed contractures or lever-arm dysfunction impair bracing and gait, surgery re-establishes joint range and foot-flat contact to enable safer walking and bracing. PMC+1

4. Chemodenervation under anesthesia (botulinum/phenol with casting)
   Procedure: Targeted injections to specific muscles, sometimes with serial casts. Why: Delay or reduce the extent of orthopedic surgery by relieving focal spasticity and improving brace tolerance. PMC

5. Hip surveillance & preventive surgery (when indicated)
   Procedure: In children or early-onset cases with adductor spasticity, preventive procedures can protect hip alignment and function. Why: Prevent painful dislocation and preserve sitting/standing mechanics. PMC

---

Preventions

1. Prevent falls: home lighting, rails, non-slip footwear, device use, and balance work. Frontiers

2. Prevent contractures: daily stretching, night splints, and timely AFOs. Frontiers

3. Prevent deconditioning: regular aerobic + strength sessions. Frontiers

4. Prevent urinary complications: bladder routines; treat UTIs fast. Frontiers

5. Prevent pressure sores: cushion, repositioning, and skin checks. Frontiers

6. Prevent pain flares: pacing, posture, activity rotation. Frontiers

7. Prevent malnutrition/sarcopenia: protein 1.0–1.3 g/kg/day with resistance exercise. PMC

8. Prevent polypharmacy harms: periodic med reviews for sedation/falls. Frontiers

9. Vaccinations & general health maintenance: reduce infection-related setbacks. NINDS

10. Genetic counseling: informed family planning and early supports. NINDS

---

When to see doctors

• New or worsening weakness, falls, or sudden gait change (rule out fractures, spinal issues, or medication effects). Frontiers

• Painful spasms not controlled by home plan (consider meds, botulinum, or ITB screening). PMC

• Bladder/bowel changes, recurrent UTIs, or incontinence needing urology input. Frontiers

• Swallowing/speech problems (SLP assessment). Frontiers

• Considering pregnancy or family planning (genetic counseling). NINDS

• Interest in “stem-cell” offers—verify FDA status or trial credentials before proceeding. U.S. Food and Drug Administration

---

Foods to favor & to limit

Eat more of:

• Olive-oil-based meals, nuts, seeds, avocado (healthy fats). Frontiers

• Fatty fish (salmon/sardines) 2–3×/week (EPA/DHA). PMC

• Legumes, tofu/tempeh, eggs, yogurt, and lean meats for protein at each meal. PMC

• Whole grains, colorful vegetables, and berries for fiber and antioxidants. Frontiers

• Adequate fluids (aim for regular, pale-yellow urine) to support bowel/bladder routines. Alberta Health Services

Limit:

• Ultra-processed foods high in added sugars and refined starch. Frontiers

• Excess alcohol (worsens balance, sleep, and spasticity). Frontiers

• Heavy, fatty meals before physio (can worsen fatigue). Frontiers

• High-sodium convenience foods (edema, BP issues). Frontiers

• “Miracle” supplements or unregulated products promising cures. U.S. Food and Drug Administration

---

FAQs

1. Is there a cure for SPG67?
   Not yet. Current care is symptomatic; research is active in gene-defined HSPs. Frontiers

2. Do all people lose walking ability?
   Progression varies. Early rehab, bracing, and fall prevention help many keep mobility longer. Frontiers

3. What is the single most helpful therapy?
   A consistent physio + strengthening + gait-adaptability plan tailored to you. PubMed

4. Can a brace really help?
   Yes—AFOs improve foot clearance and step mechanics for many people. PMC

5. Which pill works best for spasticity?
   No “best” for everyone. Baclofen, tizanidine, dantrolene, and others are tried and adjusted. PMC+1

6. What if pills aren’t enough?
   Consider botulinum toxin for focal areas or intrathecal baclofen (ITB) for severe, generalized tone. NCBI+1

7. Is dalfampridine an option?
   Approved to improve walking in MS; small HSP trials suggest possible benefit with PT—strict seizure/renal safety rules apply. FDA Access Data+1

8. Will supplements cure SPG67?
   No. They may support muscle/overall health if used wisely; check interactions and deficiencies first. PMC+1

9. Should I try stem-cell clinics?
   Avoid commercial offers outside trials; the FDA warns these are unapproved and risky. U.S. Food and Drug Administration+1

10. Can surgery straighten my legs?
    Orthopedic procedures can correct fixed contractures; selection is based on gait analysis and goals. PMC

11. Why do bladder issues happen?
    Upper motor neuron changes can trigger overactive bladder; behavioral measures and meds help. Frontiers

12. How often should I see specialists?
    At least yearly; more often if tone, gait, bladder, or pain change. Frontiers

13. Is SPG67 always “complicated”?
    Phenotypes vary; many AR HSPs have additional features. Management is based on the individual profile. Frontiers

14. What’s the best diet?
    Mediterranean/MIND-style eating supports general brain-muscle health; pair with adequate protein. PubMed+1

15. Where can I find support?
    Spastic Paraplegia Foundation and NIH/NORD resources provide education, research links, and community. sp-foundation.org+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.